Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BEPOTASTINE BESILATE vs ACTAHIST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bepotastine besilate is a selective histamine H1 receptor antagonist that inhibits histamine release from mast cells and reduces eosinophil chemotaxis, thereby suppressing allergic inflammatory responses.
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
Allergic conjunctivitis (FDA approved),Allergic rhinitis (off-label),Urticaria (off-label)
Symptomatic relief of allergic rhinitis,Urticaria,Off-label: motion sickness,Off-label: insomnia
2 mg/m L ophthalmic solution: 1 drop in each affected eye twice daily.
1.34 mg (one capsule) orally twice daily.
Terminal elimination half-life is approximately 9-10 hours in healthy adults, allowing twice-daily dosing for allergic conjunctivitis.
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
Primarily metabolized via glucuronidation (UGT1A9, UGT2B7) and oxidation (CYP3A4 minor pathway).
Hepatic metabolism via CYP450 enzymes (primarily CYP3A4 and CYP2D6); major metabolite is inactive.
Primarily renal excretion as unchanged drug (~75-80% of dose) with minor fecal elimination (~10-15%).
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
Approximately 55-60% bound to human plasma proteins, primarily albumin.
92% bound to albumin.
Following oral administration, Vd is 1.4-1.8 L/kg, indicating extensive tissue distribution. Not applicable for ophthalmic use.
0.9 ± 0.3 L/kg, indicating extensive extravascular distribution.
Oral bioavailability is <1% due to extensive first-pass metabolism. Ophthalmic: Systemic absorption negligible (<0.5%).
Oral: 68% ± 12% due to first-pass metabolism.
No dosage adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min).
No dose adjustment required for mild to moderate renal impairment. Safety not established for severe impairment (GFR <30 m L/min).
No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C).
≥2 years: same as adult dose (1 drop in each affected eye twice daily).
Not indicated for pediatric patients under 12 years of age. Safety and efficacy not established.
No dose adjustment required; same as adult dosing.
No specific dose adjustment recommended; monitor for increased anticholinergic effects and cognitive impairment.
None.
None.
May cause severe hypersensitivity reactions (angioedema, bronchospasm).,Avoid use in patients with known hypersensitivity to bepotastine.,Ophthalmic use: do not wear contact lenses during treatment; may cause transient burning/stinging.,Systemic use: caution in patients with renal impairment (dose adjustment required).,Avoid concurrent use with CNS depressants due to additive sedative effects.
May cause drowsiness; caution when driving or operating machinery. Avoid alcohol. Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or urinary retention. Geriatric patients more sensitive to anticholinergic effects. Pediatric patients <6 years: not recommended.
Hypersensitivity to bepotastine or any component of the formulation.,Severe renal impairment (Cr Cl <30 m L/min) for systemic use.
Hypersensitivity to any component. Newborns or premature infants. Breastfeeding (contraindicated due to risk of adverse effects in infants). Concomitant use with MAOIs.
No clinically significant food interactions reported with ophthalmic use.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) if taking MAOIs. Grapefruit juice may increase phenylephrine absorption; limit intake.
Bepotastine besilate is not recommended during pregnancy. Animal studies have shown no teratogenic effects at doses up to 200 mg/kg/day in rats (approximately 200 times the human clinical dose) and 100 mg/kg/day in rabbits (approximately 200 times the human clinical dose), but there are no adequate and well-controlled studies in pregnant women. During the first trimester, the risk is unknown; during the second and third trimesters, potential risks to the fetus cannot be excluded.
ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk from vasoconstrictive effects (phenylephrine) possibly reducing uterine blood flow; avoid if possible. Second/third trimester: phenylephrine may cause fetal hypoxia via placental vasoconstriction; use only if benefit outweighs risk. No known structural teratogenicity.
It is not known whether bepotastine besilate is excreted in human milk. In rat studies, drug-related material was detected in milk following oral administration. Because many drugs are excreted in human milk, caution should be exercised when bepotastine besilate is administered to a nursing woman. The milk-to-plasma (M/P) ratio has not been established for humans. Breastfeeding is not recommended during treatment.
Brompheniramine is excreted in breast milk in small amounts; M/P ratio not established. Phenylephrine has minimal excretion. Due to anticholinergic effects, may reduce milk production or cause sedation in infants. Use caution; prefer non-sedating alternatives if possible.
No dose adjustments are recommended for pregnant women based on current pharmacokinetic data. However, systemic absorption after ophthalmic administration is minimal, and no pregnancy-specific pharmacokinetic studies have been conducted. Use caution and prescribe only if clearly needed.
No specific pharmacokinetic studies. Increased plasma volume and renal clearance in pregnancy may reduce drug levels, but efficacy threshold remains. No dose adjustment recommended; use the lowest effective dose for shortest duration due to potential risks.
Bepotastine besilate is a selective histamine H1 receptor antagonist used topically for allergic conjunctivitis. Avoid use with contact lenses; remove before instillation and wait at least 10 minutes before reinserting. Systemic absorption is minimal, but caution in patients with severe hepatic impairment. Onset of action is within 15 minutes, duration 8 hours. Do not touch dropper tip to eye or surrounding surfaces.
Actahist is a combination antihistamine-decongestant (chlorpheniramine/phenylephrine). Avoid in patients with hypertension, severe coronary artery disease, or MAOI use. Monitor for sedation and urinary retention, especially in elderly males with BPH.
Wash hands before use.,Tilt head back, pull lower eyelid down, and instill one drop in the affected eye(s) twice daily.,Do not touch the dropper tip to your eye or any surface.,Remove contact lenses before use and wait at least 10 minutes before reinserting.,Do not use if solution changes color or becomes cloudy.,Common side effects include mild eye irritation, bitter taste, or headache.,If you experience eye pain, vision changes, or redness, contact your doctor.
Take with food or milk to reduce stomach upset.,Avoid alcohol and CNS depressants as they can increase drowsiness.,Do not drive or operate machinery until you know how this medication affects you.,Contact your doctor if you experience chest pain, rapid heartbeat, or difficulty urinating.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BEPOTASTINE BESILATE vs ACTAHIST, answered by our medical review team.
BEPOTASTINE BESILATE is a Ophthalmic Antihistamine that works by Bepotastine besilate is a selective histamine H1 receptor antagonist that inhibits histamine release from mast cells and reduces eosinophil chemotaxis, thereby suppressing allergic inflammatory responses.. ACTAHIST is a Antihistamine that works by Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BEPOTASTINE BESILATE and ACTAHIST depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BEPOTASTINE BESILATE is: 2 mg/m L ophthalmic solution: 1 drop in each affected eye twice daily.. The standard adult dose of ACTAHIST is: 1.34 mg (one capsule) orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BEPOTASTINE BESILATE and ACTAHIST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BEPOTASTINE BESILATE is classified as Category C. Bepotastine besilate is not recommended during pregnancy. Animal studies have shown no teratogenic effects at doses up to 200 mg/kg/day in rats (approximately 200 times the human c. ACTAHIST is classified as Category C. ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.